Last edition
News about "Janssen-Cilag International NV"
EMA Backs Marketing Authorisation for Janssen's Icotyde in Plaque Psoriasis
CHMP backs marketing authorisation for icotrokinra to treat moderate-to-severe plaque psoriasis in adults and eligible adolescents, potentially making it the first oral IL-23-targeting therapy approved in the EU.
Janssen-Cilag International N.V | 27/07/2026 | By News Bureau
European Commission Approves DARZALEX Faspro for Adults with Smouldering Multiple Myeloma
Halozyme Therapeutics has announced European Commission approval for DARZALEX Faspro, co-formulated with ENHANZE, as a monotherapy for high-risk smouldering multiple myeloma in adults, marking a shift from passive monitoring to early intervention.
Janssen-Cilag International NV | 24/07/2025 | By Mrinmoy Dey | 217
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy